Sign inCreate account

Report workspace tools

NCT04978051COMPLETEDanonymous

Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care

Sponsor

Source record

Sebastian Videla

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Firazyr, SoC

Indication / condition

AI-normalized

COVID-19 Pneumonia

Intervention

Source record

Firazyr, SoC

Source & freshness

Source record

NCT ID

NCT04978051

Original source

ClinicalTrials.gov

Source last updated

Aug 03, 2022

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04978051

Title

Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care

Sponsor

Sebastian Videla

Status

COMPLETED

Phase

PHASE2

Condition raw

COVID-19 Pneumonia

Condition normalized

COVID-19 Pneumonia

Modality raw

long COVID

Modality normalized

small molecule

Target raw

Firazyr, SoC

Target normalized

Firazyr, SoC

Interventions

Firazyr, SoC

Public preview

Source record

Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care is a PHASE2 clinical asset sponsored by Sebastian Videla in COVID-19 Pneumonia. SEO and diligence focus: Firazyr, SoC, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04978051

Status

COMPLETED

Phase

PHASE2

Sponsor

Sebastian Videla

Executive brief

Investment-Ready Snapshot

Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care is a PHASE2 clinical asset sponsored by Sebastian Videla in COVID-19 Pneumonia. SEO and diligence focus: Firazyr, SoC, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 03, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04978051

Indication

COVID-19 Pneumonia

Modality

small molecule

Target

Firazyr, SoC

Intervention

Firazyr, SoC

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.